Oura Ring Launches Blood Pressure Study for Hypertension Detection

Oura Health kicked off a Blood Pressure Profile Study in October 2025, targeting passive hypertension risk detection through the Oura Ring. This puts the Finnish company in direct competition with Samsung, Apple, and Withings, all of whom are chasing FDA clearance or CE marking for cuffless blood pressure features.

The approach here is passive detection, meaning the ring monitors physiological signals continuously without you doing anything. No cuff calibration, no dedicated measurement sessions. Oura would use photoplethysmography data from the finger, which has a denser arterial signal than the wrist readings Garmin or Apple Watch rely on.

For endurance athletes, high resting blood pressure often hides behind decent VO2max numbers. Triathletes and cyclists training 12 to 15 hours a week can still carry hypertension risk. A ring that flags that risk passively, alongside existing HRV and recovery scores, would add real clinical weight to daily readiness data.

The competition is stiff. Samsung got conditional approval for blood pressure on the Galaxy Watch in select markets years ago. Apple is still working through the regulatory pipeline. Withings has the ScanWatch 2 with blood pressure capabilities already cleared in Europe. Oura is late to this specific feature but brings stronger sleep and recovery tracking than most rivals.

Solid ambition, real clinical potential. But this is a study launch, not a finished feature. Expect 12 to 24 months before anything reaches your ring.